Abstract: A system for presenting a chance-based game. The system includes at least one server having a processor configured to execute machine-readable code. The processor is configured to cause the server to create and provide a set of 3D chance-based games to the plurality of presentation devices of the users, which each present the set of 3D chance-based games on a respective display. Each game of the set having an assigned fixed odds payout structure based on winning user selections. The server receives, over the wide area network, data from the presentation devices characterizing a set of user-selected or computer selected winners of the 3D chance-based games. The server updates the event data pertinent to participants in the actual events associated with the 3D advanced choice games. The server uses the updated data to calculate and assign payouts to the users based on the fixed payout structure.

Abstract: The present claimed invention provides a calcium ion concentration measuring device that can measure a concentration of a calcium ion in blood of a domestic animal with high accuracy without being affected by temperature on the spot where the blood is collected. The calcium ion concentration measuring device is a portable one for measuring the concentration of the calcium ion in the blood of the domestic animal, and comprises a responsive membrane that selectively reacts with the calcium ion, an internal liquid stored in a space separated from the outside by the responsive membrane, and an internal electrode arranged to be in contact with the internal liquid, and the isothermal intersection point of the internal liquid is set within a range of the concentration of the calcium ion contained in the blood of the domestic animal.

Abstract: The disclosed embodiments include devices and methods to perform inversion processing of well log data. In one embodiment, a method to perform inversion processing of well log data includes obtaining an initial model of an earth formation based on a plurality of modeling parameters that includes formation parameters of the earth formation and calibration factors associated with orientations of antennas of a logging tool utilized to measure raw measurements of the earth formation. The method also includes performing a forward modeling of the modeling parameters to obtain a modeling response, and performing a joint cost function of the first modeling response and raw measurements obtained by the logging tool. The method further includes readjusting the initial model if a result of the joint cost function is not below a threshold, and providing the modeling response if the result of the joint cost function is below the threshold.

Abstract: An electronic gaming machine performs operations comprising: (i) simulating a rotating plurality of reels, each reel of the simulated rotating plurality of reels comprising a plurality of symbols including standard symbols and bonus trigger symbols; (ii) stopping a first reel of the simulated rotating plurality of reels, wherein the first reel displays a first plurality of symbols; (iii) determining whether of the first plurality of symbols displayed include i) all standard symbols, or ii) at least one bonus trigger symbol; (iv) on at least one remaining reel of the simulated rotating reels one of: i) modifying at least one bonus trigger symbol with a standard symbol if all standard symbols are displayed, or ii) modifying the at least one standard symbol with at least one bonus trigger symbol; (v) stopping the remaining reels of the simulated rotating plurality of reels, wherein the remaining reels display a plurality of symbols; (vi) evaluating the symbols stopped and displayed from each of the simulated rot

Abstract: The problem of confirming the presence of an adulterant in a urine sample is solved by the use of a reagent capable of reacting with uric acid and non-urate markers in a urine sample. In one embodiment, a phosphotungtate reagent is used to react with the urine sample to create a blue coloration in the presence of uric acid or uric acid equivalents. A reduction or elimination of the blue coloration, resulting in a reduction in the light absorbance, of the urine sample can be used as an indicator of the historical presence of an adulterant. An Oxidant History test can also be generated using the phosphostungtate reagent, wherein the light absorbance resulting from the blue coloration is measured over time, with a measured reduction in the absorbance being an indication that an adulterant is or has been present in the urine sample and is oxidizing the uric acid and non-urate markers over time.

Abstract: Provided herein are assay control materials comprising stable analytes and lyophilized unstable analytes, and methods of making and using the same.

Abstract: The present invention is directed to methods for the production of thrombin from a source of prothrombin using a given BaSO4 reagent as an adsorbent of prothrombin as well as methods for evaluating the suitability of a given BaSO4 reagent for use in preparation of thrombin. In at least one embodiment, the method includes contacting a sample of the given BaSO4 reagent with a source of prothrombin to obtain BaSO4-adsorbed prothrombin, and subsequently evaluating the pro-coagulant activity of the BaSO4-adsorbed prothrombin. In another embodiment, the method includes the step of evaluating relative to the pro-coagulant activity of normal mammalian plasma.

Abstract: Embodiments of the present invention set forth systems, apparatuses and methods for providing conditional reel functionality in gaming devices. Accordingly, a gaming device can be configured to increase the variety of outcomes and sense of anticipation in a video slot game, by varying the composition of symbols on one or more reels based on outcomes of previously determined reels. In some embodiments this varying of composition occurs while the reels are still spinning. The varying of composition may be accomplished by modifying, substituting, generating, or otherwise altering symbols or the order of symbols in the one or more reels.

Abstract: The invention relates to a method for determining the coagulation time of a sample fluid containing blood components by means of a resonator whose vibration parameters are measured and then used as a basis for determining the sample fluid viscosity change, which resonator has an at least partially adhesive surface contacting said sample fluid. The invention is characterized by preincubation of said surface with a preincubation fluid containing blood components, which preincubation fluid has a known way of interacting with the coagulation system, thus resulting in anchoring sites to be formed on the adhesive areas of said surface.

Abstract: In some embodiments, a player may influence the volatility of a bonus round of a game by placing elements collected during a primary game onto symbol positions of the bonus round. In some embodiments, if a symbol position onto which a player placed one or more bonus round symbols is selected as an active symbol position for an event instance of the bonus round, the player wins a prize. Additionally, a multiplier may be applied to the value of the prize or other benefit may be provided to the player if the player placed more than one bonus round symbol element on the position. Thus, a player having a plurality of bonus round symbols to place may choose to increase the frequency of prizes won (e.g., by distributing the bonus round symbols over more positions) or increase the value of prizes (e.g., by grouping more symbols on fewer positions).

Abstract: An external standard solution for use in the analysis of amino acid in plasma, containing, (1) at least one amino acid selected from the following components A, at a concentration of 0.0007 M to 0.49 M, and (2) (i) at least one amino acid selected from the following components B, at a concentration of 0.2 to 0.9 times of the lowest-concentration amino acid among the amino acids selected from components A, (ii) at least one amino acid selected from the following components C, at a concentration of 0.1 to 0.4 times of the lowest-concentration amino acid among amino acids selected from the components A, or (iii) at least one amino acid selected from the following components D, at a concentration of 0.05 to 0.

Abstract: In various embodiments, players around the casino may predict cards to be dealt in a game of blackjack.

Abstract: Disclosed is a method for measuring thrombin generation in a whole blood sample. The whole blood sample may be applied forthwith, without prior processing. The blood cells and blood plasma in the whole blood sample are separated by (lateral) flow migration. Also disclosed is an assembly of a sample support and a device dedicated to measure thrombin generation in a whole blood sample. Advantageously, the sample support comprises a separator medium allowing separation of whole blood into blood cells and blood plasma by means of (lateral) flow migration.

Abstract: The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein.

Abstract: The present invention relates to a new method for the preservation of blood platelets. In particular, the present invention provides a method which includes submitting the platelets to zeodration carried out at temperatures between 18° C. and 24° C. The dried platelets thus obtained can be preserved at room temperature for long period of time. The invention also provides kits and compositions for using the preserved platelets.

Abstract: A control solution packet for calibrating a bodily fluid sampling device includes a container, a control solution pressurized within the container, and a membrane for covering and sealing the container. The control solution can be pressurized before or during calibration so as to ensure the appropriate amount of control solution is delivered to the bodily fluid sampling device. The control solution is manufactured to have a viscosity that controls delivery of the control solution to the device. The membrane is permeable by a piercing device of the bodily fluid sampling device and seals around the piercing device during calibration. In another aspect, the container is in the form of a capsule or dosing attachment that contains the control solution along with a sponge-like material.

Abstract: A method for determining an appropriate treatment option for a patient who has been diagnosed with disseminated intravascular coagulation (DIC) but who may have thrombotic thrombocytopenic purpura (TTP), by analyzing the amount and/or enzyme activity of a von Willebrand factor (vWF)-cleaving protease (ADAMTS13) and the amount of vWF in a patient that has been diagnosed with DIC is disclosed. Using the method of the present invention, a differential diagnosis of patients with thrombotic thrombocytopenic purpura (TTP) can be made from among patients diagnosed with DIC, which could not previously be distinguished on the basis of only clinical findings or known markers. Also disclosed is a kit for determining an appropriate treatment option, the kit comprising an antibody or a fragment thereof which specifically binds to ADAMTS13.

Abstract: Disclosed is a convenient and effective means for quantifying an antigen-specific canine or human IgE.

Abstract: The invention provides a serum or plasma separating composition which can compensate for the lack of initial thixotropy even at a reduced inorganic powder concentration and in which crevices or the like are less likely to be created in a partition wall formed of the separating composition after being centrifuged. The serum or plasma separating composition contains a liquid resin component having a partition wall-forming capability, a hydrophilic inorganic powder, a hydrophobic inorganic powder, and an organic compound serving as a thixotropy enhancer, wherein the organic compound is a polyalkylene glycol and/or a derivative thereof and is made of at least one type of polymer.

Abstract: An object of the present invention is to provide a control material which can be preferably employed in detection of 1,5-anhydro-D-glucitol and glycoalbumin, which are employed as excellent indices for diabetes. The present inventor has found that mannitol which is added to serum or plasma used as control material stabilizes 1,5-anhydro-D-glucitol and glycoalbumin present in the serum or plasma for a long period of time, and that the object can be attained through provision of (1) an agent for stabilizing control material, the agent being composed of mannitol and (2) control material containing mannitol and 1,5-anhydro-D-glucitol.

Abstract: A separator (1a) under the invention for the taking of blood serum or blood plasma contained in a blood sample from a separating strip comprises a top part (3), a bottom part (4) and a joint (5). Said top part (3) and bottom part (4) are linked by the joint (5) in a pivoting way. Bottom part (4) is designed to support the separating strip. At least one nose (7a, 7b) is provided at the bottom part (4) and/or underside of top part (3) which can exert local pressure on the separating strip once top part (3) and bottom part (4) are folded together thus pressing blood serum or blood plasma out of the rear end of the separating strip.

Abstract: A method of removing abnormal data in a blood component analysis system using spectroscopy to estimate a concentration of a blood component by analyzing a photo-plethysmographic (PPG) signal obtained by radiating light of first and second wavelengths reacting to the blood component on a subject and detecting light corresponding to the first and second wavelengths output from the subject, includes collecting the PPG signal corresponding to the first and second wavelengths for a predetermined unit period of time, calculating “n” parameters, with respect to “n” pulse data included in the collected PPG signal, where n is a positive integer, calculating an average of the “n” parameters, and comparing a ratio of a number of parameters whose deviation from the average is greater than a predetermined standard deviation to the “n” parameters with a predetermined removal reference value to determine whether the “n” pulse data is valid.

Abstract: A gaming machine connected in a gaming network or operating as a stand-alone machine, is capable of accepting two or more currencies for wager game play. The machine operates internally using a native monetary type and converts non-monetary bills to native amounts in the form of restricted or cashable credits. The multiple currency capability of the machine is utilized to encourage the use of restricted credits by adjusting conversion rates, payback tables, and the like. These features, combined with the use of restricted credits, also enable ways to monitor abuse and illegal activity on the gaming machine and implement ways to limit losses by a player. Certain post-conversion processes are used to ensure that the player is returned non-converted amounts. The gaming machine has additional hard and soft meters to process multiple monetary types.

Abstract: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.

Abstract: A gaming system including a central server linked to a plurality of gaming machines and a plurality of bonus awards. The central server monitors wagers on the gaming machines. Based at least in part on the wagers the central server determines when bonus events will occur and which gaming machine(s) will provide the bonus awards. In one embodiment, the central server determines which gaming machine will provide a primary bonus award and any secondary bonus awards, wherein at least one gaming machine may be provided a plurality of bonus awards.

Abstract: A reagent for detecting an analyte by a redox reaction and a fluorimetric determination is disclosed. The reagent comprises a compound of formula (I): wherein R1 and R2 are each independently selected from R, (CH2CH2O)mR, COR, COOR, and OCOR; each R3 is independently selected from NO2, CN, R, OR, OCOR, COOR, SR, and halogen; R is H or C1-C4 alkyl, where alkyl is optionally substituted with one or more functional group independently selected from the group consisting of halogen, OR, SR, NR2, COOR, CONR2, SO3R and salts thereof, and PO(OR)3 and salts thereof; m is an integer from 1 to 20; and n is 1, 2, or 3. The reagent may further comprise an enzyme or a coenzyme for reducing or oxidizing an analyte.

Abstract: A method of playing a wagering game comprises receiving a wager, and generating a randomly selected first outcome of a first wagering game, the first outcome comprising a first plurality of symbols arranged in a first matrix. The method further comprises generating a randomly selected second outcome of a second wagering game, the second outcome comprising a second plurality of symbols arranged in a second matrix, and simultaneously displaying the first outcome and the second outcome on at least one display. The method further comprises detecting an occurrence of a triggering event, in response to the triggering event, copying a first special symbol occurring in the first outcome into the second outcome to yield a modified second outcome, and evaluating the first outcome and the modified second outcome for winning combinations of symbols.

Abstract: A liquid for discharge includes: a biospecimen; and at least one kind of compounds represented by the formula (1). In the formula (1), m?8, and 6?n?20.

Abstract: Disclosed are methods for conducting assays of samples, such as whole blood, that may contain cells or other particulate matter. Also disclosed are systems, devices, equipment, kits and reagents for use in such methods. One advantage of certain disclosed methods and systems is the ability to rapidly measure the concentration of an analyte of interest in blood plasma from a whole blood sample without blood separation and hematocrit correction.

Abstract: The invention features methods and compositions for diagnosis, including prognosis, of conditions associated with decreased arginine bioavailability (which can result from dysregulated arginine metabolism, e.g., due to increased arginase activity) by assessing in a sample from a subject the ratio of arginine to one or more, usually two or more, modulators of arginine bioavailability. In one embodiment, the ratio of arginine to (ornithine+citrulline) is assessed to aid in diagnosis.

Abstract: Disclosed are methods for conducting assays of samples, such as whole blood, that may contain cells or other particulate matter. Also disclosed are systems, devices, equipment, kits and reagents for use in such methods. One advantage of certain disclosed methods and systems is the ability to rapidly measure the concentration of an analyte of interest in blood plasma from a whole blood sample without blood separation and hematocrit correction.

Abstract: A game of chance is disclosed that looks like a multi-line gaming machine having a matrix of rows and columns of positions for displaying slot symbols or cards to a player. A player wagers to play one or more games but the actual pay lines are dynamically determined by events that occur during the course of game play, not before. Per the teaching of the invention a number of bonus pay lines and their routing are dynamically determined during the course of game play of slots or cards dependent on choices made by a player during game play.

Abstract: The present invention relates to the field of the distinction between bacterial meningitis and viral meningitis. It relates in particular to an in vitro method for detecting the presence of bacterial meningitis, which comprises determining the concentration of procalcitonin present in a test blood sample and of proteins present in a test cerebrospinal fluid sample, and comparing the concentrations thus determined to the concentration of procalcitonin and of proteins present in a reference sample or to a reference value. It also relates to a kit comprising means for detecting procalcitonin and proteins in the cerebrospinal fluid, and to the use thereof for the production of a diagnostic tool for bacterial meningitis.

Abstract: A method for preparing a composition that includes selecting a pH of the composition; selecting a first buffer with a negative temperature coefficient; selecting a second buffer with a positive temperature coefficient; and forming the composition comprising the first buffer and the second buffer. The composition has an average temperature coefficient, ?pH/?T(Ta,Tb)?1×10?3 pH-unit/K and a ?pH(Ta,Tb)?0.31 pH-unit for Ta=4 K and Tb=313 K.

Abstract: The present invention provides fluidic devices and systems that allow detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications.

Abstract: The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein.

Abstract: A method of detecting thrombosis or the degree of thrombophilia by measuring a von Willebrand factor cleaving protease, and a kit for detecting thrombosis or the degree of thrombophilia, comprising an antibody or a fragment thereof specifically binding to a von Willebrand factor-cleaving protease, are disclosed. The detection method and the detection kit have an excellent convenience, rapidity, and specificity.

Abstract: Methods and reagents are disclosed for detecting a false result in an assay for determining a concentration of an analyte in a whole blood sample suspected of containing the analyte. The method comprises determining by means of the assay a concentration of the analyte utilizing a hemolyzed portion of the blood sample to obtain concentration value 1 and determining by means of the assay a concentration of the analyte utilizing a non-hemolyzed portion of the blood sample and multiplying the concentration times a hematocrit factor to obtain concentration value 2. A ratio of concentration value 1 divided by concentration value 2 is determined and is compared to a predetermined ratio of known reliability. If the ratio is less than the predetermined ratio, a false result is indicated.

Abstract: Control and calibration solutions are described that provide control and calibration data that is recognized by a test meter allowing the meter to segregate the control and calibration data from regular test data. Recognition and segregation of the control and calibration data can occur automatically with no additional input from the meter's user. Methods for use of the solutions are also provided.

Abstract: A control solution packet for calibrating a bodily fluid sampling device includes a container, a control solution pressurized within the container, and a membrane for covering and sealing the container. The control solution can be pressurized before or during calibration so as to ensure the appropriate amount of control solution is delivered to the bodily fluid sampling device. The control solution is manufactured to have a viscosity that controls delivery of the control solution to the device. The membrane is permeable by a piercing device of the bodily fluid sampling device and seals around the piercing device during calibration. In another aspect, the container is in the form of a capsule or dosing attachment that contains the control solution along with a sponge-like material.

Abstract: A method for adjusting the coagulation time during the manufacture of calibrators and controls produced from frozen plasma or plasma treated for lyophilization thereof, for haemostatis tests relating to assaying and to monitoring anticoagulant treatments in a patient. The plasmas selected to prepare the calibrator plasmas or the control plasmas are treated with a view to lyophilization and supplemented with different predefined doses of a drug and a procoagulant factor.

Abstract: Disclosed are methods for detecting antibody in a sample, where the antibody targets an antigen expressed by red blood cells or red blood cell ghosts. Rather than detecting the binding events between a particular antigen antibody pair (as in traditional agglutination based assays) the methods herein allow for multiplexed detection of clinically important allo-immune antibodies to blood group antigens. Specifically the method involves generating fluorescently encoded red blood cells or red blood cell ghosts with known antigen presentation and using them to detect the presence of antibody in serum/plasma with a fluorescent sandwich type immunoassay. The assay results can be read using flow cytometric or fluorescent microscope based imaging techniques.

Abstract: There is disclosed a method of diagnosing early stage renal impairment in humans, characterized by the following steps: measuring the amount of apoA-IV in a body liquid or tissue sample of a human, and comparing the measured amount of apoA-IV with a reference value.

Abstract: An gaming machine for and method of par-mutuel wagering that allows individuals to continuously place multiple casino and lottery styled pari-mutuel wagers on simulcast live and/or recorded pari-mutuel race events. The gaming machine includes a display screen to provide a graphic display of a plurality of pari-mutuel gaming options to a player, and a selection device operable by the player to select at least one of the pari-mutuel gaming options displayed on the screen, the selection device operable by the player to input a wager corresponding to the selected at least one pari-mutuel gaming option. The gaming machine has the ability to be linked to a network of gaming machines in pari-mutuel and/or other wagering venues.

Abstract: The invention concerns a method which consists in determining ageing an ageing index of a blood bag (11, 62), to determine whether the blood bag is or not suitable for transfusion to a patient. The ageing index is calculated by connecting a silicon chip provided with a loop antenna integral with the blood bag (11, 62) with an electronic communication device (2, 8, 17, 12, 20, 24), itself equipped with a loop antenna, connected to a computer (9, 13) containing appropriate computing software elements. Said ageing index is regularly calculated at the blood transfusion center (16) from the sample (1), until it is removed from storage (7) to be sent to the health-care institution (18) and to the operating theatre (19).

Abstract: Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for stroke. The invention provides a diagnostic assay for either of these markers, preferably by ELISA using a anti-H-FABP or B-FABP antibody. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish stroke from AMI requires an assay specific to AMI, e.g. using troponin-1 or CK-MB as a marker, also to be carried out.

Abstract: The present invention provides a reference solution for use in instruments that determine hematocrit levels in biological samples by measuring the resistance and/or conductivity of the biological samples. A reference solution according to the invention achieves conductivities representative of known hematocrit levels in blood, while maintaining tolerable levels of interference with the measurement of other analytes in the reference solution.

Abstract: A urine analysis system includes a urinary particle analyzer and a computer. The urinary particle analyzer has a measuring unit that measures a cast concentration from the urine and an electric conductivity sensor that measures the electric conductivity of the urine. The computer has a function of correcting the cast concentration measured by the measuring unit on the basis of the electric conductivity of the urine measured by the electric conductivity sensor and a function of outputting the corrected cast concentration.

Abstract: The present invention provides a method of determining whether an individual is at risk for atherosclerosis, comprising the step of measuring the level of cLDL and/or autoantibody to cLDL in a sample obtained from this individual. The invention further discloses a method of reducing carbamylation in an individual with a monomeric amino acid or other enzymatic or non-enzymatic inhibitors of carbamylation. The instant invention also provides a method to decrease the level of cLDL by direct elimination of cLDL from the blood or plasma of an individual. The invention also provides a method of treating or preventing atherosclerosis in an individual by inhibiting aggregation and/or deposition of cLDL in the individual.

Abstract: The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.